SlideShare ist ein Scribd-Unternehmen logo
1 von 10
Downloaden Sie, um offline zu lesen
1
©2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4.0/
Multiple Sclerosis and Related Disorders. DOI: 10.1016/j.msard.2016.09.007
How to refer to people with disease in research outputs: The disconnection between academic
practice and that preferred by people with multiple sclerosis.
David Bakera
; Ananthi Anandhakrishnana
; Katie A. Tuite-Daltonb
; Hazel Lockart –Jonesb
; Rodden
M. Middletonb
; David V. Fordb
; Christina Crowec
; Gavin Giovannonia
1
Neuroimmunology Unit, Blizard Institute, Barts and the London, Queen Mary University of London
2
College of Medicine, Swansea University, Swansea, Wales, United Kingdom
3
North American Research Committee on Multiple Sclerosis (NARCOMS), The University of Alabama
at Birmingham, Birmingham, Alabama, USA
Correspondence:
Prof. D. Baker,
Neuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry,
Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom
Tel: +44 20 7882 8954; Fax: +44 20 7882 2180; Email: david.baker@qmul.ac.uk
HIGHLIGHTS
 Someone who has MS prefers to be described as a “person with MS”
 People with MS do not want to be referred to as a “sufferer” or “client”
 Researchers largely used the term “Patient”, which is not particularly liked by people with
MS
 A simple change to practises of use of descriptors of MS may help the Patient and Public
Involvement (PPI) process
2
ABSTRACT
BACKGROUND: Increasingly, Government and Charity funders require public engagement in
research. Invariably these research outputs describe the condition of someone with the disease of
interest. We therefore sought to identify the preferred descriptor of someone with a disease, such
as multiple sclerosis (MS) and to determine what descriptors are currently used by academics.
METHODS: Several surveys were undertaken: one from the Research Network of the MS Society
(MSSRN), a major MS Charity within the United Kingdom, who are involved in reviewing grant
applications, priority setting and research governance (n=146), and surveys from both the United
Kingdom MS register (MSR; n=1713) and the North American Research Committee on Multiple
Sclerosis (NARCOMS) registry (n=518). People were asked to rate descriptors of someone affected
with MS. These were compared to that used by academic experimenters in basic science and clinical
science research papers.
RESULTS: Although the frequency of responses varied between surveys the overall findings showed
many consistencies. This included use of person/people with MS (pwMS) as the preferred descriptor
for someone with MS for social media and scientific publications. This was the preferred choice in
about 55-60% people from the MRS and in over 70% in the NARCOMS and the MSSRN, respectively.
Although MSer was the second preferred–choice for use in social media, there was as a large range
of preferences from the ‘most-preferred’ to the ‘most-disliked.’ This reflected an earlier survey by
UK-based research blogs using the term MSer (n=173). In contrast, pwMS had few ‘dislikes’ and
results were skewed towards the ‘liked’ and ‘most-preferred’ choices. Client and sufferer were
generally disliked terms, although there was some regional variation in levels of choice. Patient was
generally seen as a neutral term that was neither strongly liked nor disliked. However, patient
gained more public support for use within scientific publications (~20-25%) compared to social
media (~10–15%). This descriptor was however most commonly used (98–99%) within both pre-
clinical (searched in 6-month output of preclinical autoimmune MS models; n=161) and in clinical
publications (specialist MS journals; n=220), whereas pwMS was not reported in over 75% of papers
published in some specialised MS journals, and did not appear in the pre-clinical animal studies
examined.
CONCLUSION: There is a clear disconnection between preferences by individuals living with MS and
current academic practise. As pwMS are increasingly reading primary research publications and are
involved in patient and public involvement in research and grant review activities, the sensitivities of
lay readers should be considered when writing research outputs. This issue may affect other
diseases and a change in writing style could be adopted to show that we respect the wishes of the
people that we study and wish to help.
KEYWORDS
multiple sclerosis; public engagement; patient public Involvement; social media; surveys
ABBREVIATIONS
IQ Intelligence Quotient
MS Multiple Sclerosis
MSR MS Register
MSSRN MS Society Research Network
NARCOMS North American Research Committee on Multiple Sclerosis
PPI patient and public involvement
PwMS person/people with MS
3
1. INTRODUCTION
Multiple sclerosis (MS) is an immune-mediated, demyelinating and neurodegenerative disease of the
central nervous system that affects about 2.5 million people worldwide (Compston & Coles 2008).
The disease is insufficiently controlled by currently available treatments and therefore people utilize
the internet to investigate research and treatments options (Brigo et al. 2014). There is a an
increasing will amongst Government and Charity funders of research that there is patient and public
involvement (PPI) in research and a strong aspect of public engagement in science. This includes the
production of ‘open access’ research outputs, such that people paying for the research have access
to the findings. This supports the development of an increasingly knowledgeable number of people
with MS, who are reading original academic articles as they try to understand their disease and
treatment options. Furthermore, members of the public are involved in review panels for ethics and
research grant applications, all of which require a lay summary as part of the funding process.
To find a neutral term that best describes someone with MS, is empowering for people living with
the disease, is non-patronizing and does not entrench stereotypes, we performed some surveys
centred on web-based questionnaires (n=396) in which MSer was identified (Baker et al. 2014a). In
our initial studies, people with MS (pwMS) did not like being called client, which is a ‘politically-
correct’ term used by health economists, but also preferred not to be called a patient or an MS
sufferer. In contrast pwMS received a good deal of support. The original surveys were from people
visiting a United Kingdom (UK)–based, MS research blog (www.ms-res.org) and ShiftMS
(www.shift.ms), which is a social media community for young people affected by MS. These sites
used the term ‘MSer’, originating from the founders of ShiftMS, and therefore may have influenced
the preferences of people taking the surveys. Therefore to examine this is further, different groups
of people with MS were surveyed and the results were compared to that used by the academic
community.
2. METHODS
2.1 Multiple Sclerosis Society Research Network Survey
In consulting with the Queen Mary University of London Research Ethics Committee no personal
identifiers were collected as part of this and previous surveys (Baker et al. 2014a). By completing the
surveys, participants provided implied consent for publication of results, as indicated by disclaimers.
A web link to an anonymous survey was sent, via the Multiple Sclerosis Society in the United
Kingdom, to members (n=315) of the MS Society Research Network (MSSRN). This is a PPI network
of people personally affected by MS, who are involved in priority setting, reviewing grant
applications, governance of the research programme, advisory groups and other ad hoc PPI
activities. (www.mssociety.org.uk/ms-research/get-involved-in-research/research-network). People
in the MSSRN survey were asked how someone with MS should be referred to with 5 set options
(Client; MSer; Sufferer; Patient; PwMS that were selected previously (Baker et al. 2014a)), and asked
to rank these on a 1–5 scale, from most preferred to least preferred.
2.2 UK MS Register
The UK MS Register (MSR) received peer review via MS Society mechanisms and has ethical approval
from the South West–Central Bristol Research Ethics Committee (11/SW/0160) as a research
database (Ford et al. 2012). Although identifiable information was collected via the MS register, this
was only used to create data linkages such that the functioning UK MS Register contains only
anonymous data accessed and analysed within a Safe Haven environment, with scrutiny of research
outputs before release (Ford et al. 2012; Jones et al. 2014). The survey was performed, hosted and
analysed by the UK MS register.
2.3 North American Research Committee on Multiple Sclerosis registry
North American Research Committee on Multiple Sclerosis (NARCOMS) registry (www.narcoms.org;
Kister et al. 2013) following ethical review by the University of Alabama at Birmingham (UAB)
Institutional Review Board, sent the link to the original survey circulated to the MSSRN, to the
NARCOMS registry.
4
2.4 Academic use of descriptors of pwmS. As part of a previous study [Baker et al. 2014b], 161
primary research papers concerned with experimental autoimmune encephalomyelitis studies,
which were published over a six-month period in 2012 had been downloaded [Baker et al. 2014b].
These were analysed for which descriptors were used. In addition the total publication outputs of
some MS specialist clinical journals for the same year were analysed. We searched papers in:
Multiple Sclerosis and Related Disorders (n=42), Multiple Sclerosis Journal (n=220) and Multiple
Sclerosis International (n=23). These were read to determine which descriptors were used.
3. RESULTS
3.1 The preferential descriptor for someone with multiple sclerosis-The patient perspective
Following surveying the research network of the Multiple Sclerosis Society there were n=146
responses. The vast majority of people (about 70% of preferred responses in MSSRN) preferred the
use of pwMS, while client was the least preferred (about 2–3% of the preferred responses) (Table 1;
Figure 1). Although MSer was the second choice by the MSSRN for use in social media (Table 1), it
was clear this was either a most-liked or disliked term, as also found in a sub-study (n=173) of the
original surveys (Baker et al. 2014a) undertaken (Figure 1). In the survey of the MSSRN about 49% of
responses selected MSer as a first or second (Preferred) choice, compared to 95% pf responses for
pwMS, which was universally preferred, and 11% of the responses for client, which was the least
preferred (Figure 1). Similarly 34% of responses that selected MSer were the last and second from
last choices (Disliked) compared to 1% for pwMS or 70% for client (Figure 1). Patient was neither
really liked (25% of response for patient) or disliked (36% of responses for patient) and most
responses (39%) centred on the median preference. However, for use in scientific papers about 48%
of the two most-preferred choices liked the use of patient compared to about 18% who disliked the
use of patient. Again 96% of the top two responses preferred the use of pwMS and 0% of the two
least-preferred responses disliked the use of pwMS. Thus, there were similarities in the overall types
of responses in this new survey compared to one of the original surveys (Baker et al. 2014a), which
addressed the same questions (Figure 1), although it was clear that pwMS was the preferred choice.
To achieve independent replication, the survey was performed, hosted and analysed by the UK MS
register. There were a total of 1713 responses to the survey over a two-week period and as per
protocol, only completed responses were included in the analysis. Again there was a clear
preference (54–58%) for the use of pwMS as a descriptor of someone with MS. Incomplete answers
in the other surveys tended to only include 1–3 choices, often with pwMS as the most preferred, and
this figure may therefore slightly underestimate the clear preference for use of pwMS. Likewise,
again use of client was an infrequently preferred choice (6% of responses) (Table 1. Figure 2). MSer
again had some preference for use in the social media (Table 1), but was again found to be a term
that was either liked or disliked (Figure 2). Similarly, the use of MS sufferer was either disliked or
liked with a trend for the term to be disliked in both social media and the academic literature (Figure
2). Whilst MSer may lack familiarity and thus account for the wide range of preferences observed
(Figure 1, Figure 2), opinion may change as indicated by a more positive view from pwMS about
MSer surveyed from sites that use the descriptor (Figure 1). Again, most notably in relation to use for
social media, the use of patient was neither liked nor disliked (Figure 2). However, there was a
greater preference for the use of patient in scientific publications (Table1; Figure 2). Thus, the trends
identified in this large survey reflect those found in the smaller UK–based surveys (Figure 1; Figure
2).
The web link used by the MSSRN was also hosted by the NARCOMS registry. Again, the preferred
descriptor was pwMS for use in both social and academic media (n=518; Table 2; Figure 3). Similar to
surveys by the MSSRN and MSR, here the preference for use of MSer was wide ranging. Likewise,
patient was also neither most liked nor disliked for use in social media, although again use of patient
was considered more acceptable in scientific outputs (Table 1; Figure 3). Client again tended to be
disliked, although there appeared to be a greater acceptance of this politically-correct term than in
the UK-based surveys (Figure 1-3). Likewise, use of the term sufferer suggested some national
differences in acceptance of descriptor terms (Figure 3). Sufferer was largely disliked in the North
American NARCOMS survey compared to the British MSR survey (Figure 3). As such, 33.6% of MSR
5
respondents “liked” or “most preferred” the use of sufferer, compared to only 14% of people in
North America (P<0.001 Chi-squared Test). The underlying reasons behind this difference require
further investigation, however the United Kingdom has poor access to disease modifying treatments
(Kobelt & Kasteng 2009) and thus may be more likely to feel that they are suffering. Nevertheless in
conclusion, it is clear that pwMS is the universally preferred descriptor of someone with MS for both
social media and academic research outputs.
3.2 The preferential descriptor for someone with multiple sclerosis-Academic use
In an attempt to determine what descriptors MS researchers use (Table 2), we analysed primary
research papers concerned with experimental autoimmune encephalomyelitis (EAE) studies (n=161),
published over 6 months [Baker et al. 2014b]. We also analysed the total publication outputs of
some MS specialist clinical journals for the same year. In these journals we found that 114 pre-
clinical, basic science papers about EAE described someone with MS. In the vast majority (98%) of
cases, patient was used to describe someone with MS. Additional descriptors were used and MS
sufferer or someone suffering from MS was used in 8% of papers describing pre-clinical studies
(Table 2). However, this term did not appear in the papers in clinical journals examined (Table 1).
Basic scientists sometimes also use MS sufferer, in their grant applications (unpublished
observations). However, it is clear that academics largely use patient, as this occurred in 98-99% of
published papers (although about a quarter of papers published in clinically-oriented journals used
pwMS (Table 2)). Therefore there is a disconnection between that used by MS researchers and that
preferred by pwMS.
4. DISCUSSION
There is clearly a disconnection between pwMS-preference and that used by academia, suggesting
that change is needed. As lay pwMS are commonly reading and appraising research grants as part of
the PPI process, academics should consider the sensitivities of how best to refer to someone with
MS. Simple consideration to these issues should be made during grant and paper-writing, as they
are simple to implement. Although sufferer, which is more common in the tabloid media, was not
commonly used in the medical journals, patient has its origins in Latin from the verb pati, to suffer,
and through the participle form patientem, for one who is suffering. Patient is currently defined as a
person who is under medical care or treatment and thus still carries a perhaps an out-dated
paternalistic aura. This may need change as modern medicine evolves and decision-making is
becoming a shared experience between the patient and caregiver. The medical profession has a
history of being adaptive to change in relation to the description of people in their care; for example,
the historical, medical use of: moron (Intelligence Quotient (IQ) <25), imbecile (IQ25-50) and idiot (IQ
50-70) as a measure of mild, moderate and profound mental retardation has ceased, as their use is
considered politically incorrect and offensive by society.
Concern has been expressed that any form of label can be used as a means for division and
prejudice. With the need to have descriptors, the term pwMS was the preferred method for current
description. This should be used in preference to ‘patient’ and use of both MS sufferer and MS client
should be avoided. Whilst this aspect has been examined here in relation to MS, it is probably
unlikely that the academic use of ‘patient’ and preference for ‘person with’ to describe any other
condition is not the current norm. Therefore, a simple change in writing style could and should be
adopted, if we are to show that we respect the wishes of the people that we serve and wish to help.
FUNDING: This research received no specific grant from any funding agency in the public,
commercial or not-for-profit sectors.
ACKNOWLEDGEMENTS: The authors thank the assistance of the Multiple Sclerosis Society, notably
Ms. Mital Patel. The MS Register gratefully acknowledges the support of the Multiple Sclerosis
Society. NARCOMS acknowledges support from the Consortium of Multiple Sclerosis Centers, the
National Multiple Sclerosis Society and unrestricted grants from pharmaceutical companies.
CONFLICTS OF INTEREST: None relevant
6
REFERENCES
Baker D, Pepper G, Yauner F, Giovannoni G. MSer - A new, neutral descriptor for someone with
multiple sclerosis. Mult Scler Relat Disord. 2014a; 3:31-33.
Baker D, Lidster K, Sottomayor A, Amor S. Two years later: journals are not yet enforcing the ARRIVE
guidelines on reporting standards for pre-clinical animal studies. PLoS Biol. 2014b; 12:e1001756.
Brigo F, Lochner P, Tezzon F, Nardone R. Web search behavior for multiple sclerosis: An
infodemiological study. Mult Scler Relat Disord. 2014; 3:440-443.
Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372:1502-1517.
Ford DV, Jones KH, Middleton RM, Lockhart-Jones H, Maramba ID, Noble GJ, Osborne LA, Lyons RA.
The feasibility of collecting information from people with Multiple Sclerosis for the UK MS Register
via a web portal: characterising a cohort of people with MS. BMC Med Inform Decis Mak. 2012;
12:73.
Jones KH, Jones PA, Middleton RM, Ford DV, Tuite-Dalton K, Lockhart-Jones H, Peng J, Lyons RA,
John A, Noble JG. Physical disability, anxiety and depression in people with MS: an internet-based
survey via the UKMS Register. PLoS One. 2014; 9:e104604.
Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Herbert J. Natural history of multiple
sclerosis symptoms. Int J MS Care. 2013; 15: 146-158.
Koberlt G, Kasteng F. Access to innovative treatments in multiple sclerosis in Europe. 2009, pg3:1-
3:20 European Federations of Pharmaceutical Industry Associations.
7
Table1 Descriptors most preferred by People with MS to describe someone with MS
Most preferred descriptor of someone with multiple sclerosis
Descriptor MS Blog MSS Research
Network
NARCOMS UK MS Register
Social Academic Social Academic Social Academic
Client 2% 3% 2% 4% 3% 6% 6%
MSer 47% 18% 5% 11% 3% 17% 12%
pwMS 42% 70% 67% 76% 67% 58% 54%
Patient 10% 3% 15% 7% 23% 9% 21%
Sufferer 6% 8% 14% 2% 4% 12% 16%
Anonymous surveys were undertaken via: a MS blog site (n=174. Baker et al. 2014a); the UK MS
Society Research Network (n=146); NARCOMS (n=518) and the UK MS Register (n=1731). It was
requested that respondents ranked their most preferred descriptor for being referred to in either
the social media or within academic media. In the MS Blog, MSSRN and NARCOMS surveys some
responses recorded equal preferences. In the MS register survey, only data from fully competed
surveys with a single preference were included in the analysis (n=1582–1618).
Table2 Descriptors used to describe someone with MS in academic papers
Frequency of descriptor of someone with multiple sclerosis in
academic papers
Descriptor Basic Science Papers Clinical MS Special Journals
Client 0% 0%
MSer 0% 0%
pwMS 1% 24%
Patient 98% 99%
Sufferer 8% 0%
Published papers on pre-clinical studies using animal models of MS (n=114) and papers published in
clinically-related, MS-specialist journals (n=285) were read and frequency of the descriptor, which
may have contained multiple descriptors within one study, used to describe of someone with MS
was recorded.
8
Figure 1. Preferred descriptors used to describe someone with MS
FrequencyofResponses(%)
0
10
20
30
40
50
60
0
10
20
30
40
50
60
FrequencyofResponses(%)
CLIENT
MSer
0
10
20
30
40
50
60
MSer
0
10
20
30
40
50
60
PATIENT
0
10
20
30
40
50
60
PATIENT
FrequencyofResponses(%)
FrequencyofResponses(%)FrequencyofResponses(%)
0
10
20
30
40
50
60
CLIENT
Most
Disliked
FrequencyofResponses(%)
0
10
20
30
40
50
60
Neutral
Response
Most
Liked
Disliked Liked
CLIENT
0
10
20
30
40
50
60
70
80
PERSON WITH MS
0
10
20
30
40
50
60
MS RESEARCH BLOG PREFERENCE CHARITY RESEARCH NETWORK PREFERENCE
FrequencyofResponses(%)
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
FrequencyofResponses(%)
MS SUFFERER
0
10
20
30
40
50
60
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
MS SUFFERER
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
PERSON WITH MS
FrequencyofResponses(%)
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
An anonymous survey was undertaken via (a) an MS research blog (Baker et al. 2014a) and (b) the
MS Society Research Network. It was requested that respondents ranked the quality of/their most
preferred descriptor for being referred to. The data represent the frequency distribution or each
preference on the research blog (n=173) or preference of how to describe someone with MS on
Social media (n=111–140).
9
Figure 2. Preferred descriptors used to describe someone with MS on the UK MS Register
FrequencyofResponses(%)
0
10
20
30
40
50
60
0
10
20
30
40
50
60
FrequencyofResponses(%)
CLIENT
MSer
0
10
20
30
40
50
60
MSer
0
10
20
30
40
50
60
PATIENT
0
10
20
30
40
50
60
PATIENT
FrequencyofResponses(%)
FrequencyofResponses(%)FrequencyofResponses(%)
0
10
20
30
40
50
60
CLIENT
Most
Disliked
FrequencyofResponses(%)
0
10
20
30
40
50
60
Neutral
Response
Most
Liked
Disliked Liked
CLIENT
0
10
20
30
40
50
60
PERSON WITH MS
0
10
20
30
40
50
60
SOCIAL MEDIA PREFERENCE SCIENTIFIC PUBLICATION PREFERENCE
FrequencyofResponses(%)
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
FrequencyofResponses(%)
MS SUFFERER
0
10
20
30
40
50
60
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
MS SUFFERER
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
PERSON WITH MS
FrequencyofResponses(%)
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
A survey was undertaken via the UK MS Register. It was requested that respondents ranked their
most preferred descriptor for being referred to in either: Social Media or within Academic
Publications. The data represent the frequency distribution or each preference from fully completed
surveys that used recorded only a single preference (n=1582–1618).
10
Figure 3. Preferred descriptors used to describe someone with MS on the NARCOMS registry
FrequencyofResponses(%)
0
10
20
30
40
50
60
0
10
20
30
40
50
60
FrequencyofResponses(%)
CLIENT
MSer
0
10
20
30
40
50
60
MSer
0
10
20
30
40
50
60
PATIENT
0
10
20
30
40
50
60
PATIENT
FrequencyofResponses(%)
FrequencyofResponses(%)FrequencyofResponses(%)
0
10
20
30
40
50
60
70
80
Most
Disliked
FrequencyofResponses(%)
0
10
20
30
40
50
60
Neutral
Response
Most
Liked
Disliked Liked
CLIENT
0
10
20
30
40
50
60
70
80
PERSON WITH MS
0
10
20
30
40
50
60
SOCIAL MEDIA PREFERENCE SCIENTIFIC PUBLICATION PREFERENCE
FrequencyofResponses(%)
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
FrequencyofResponses(%)
MS SUFFERER
0
10
20
30
40
50
60
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
MS SUFFERER
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
PERSON WITH MS
FrequencyofResponses(%)
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
Most
Disliked
Neutral
Response
Most
Liked
Disliked Liked
An anonymous survey was undertaken via the NARCOMS registry website (www.narcoms.org). It
was requested that respondents ranked their most preferred descriptor for being referred to in
either: Social Media or within Academic Publications. The data represent the frequency distribution
of each preference (n=454–509).

Weitere ähnliche Inhalte

Was ist angesagt?

JournalofHospitalMedicine
JournalofHospitalMedicineJournalofHospitalMedicine
JournalofHospitalMedicineScott Hao
 
Fuller et al-2015-head_&amp;_neck
Fuller et al-2015-head_&amp;_neckFuller et al-2015-head_&amp;_neck
Fuller et al-2015-head_&amp;_neckShashwat Mishra
 
Influence of medicare formulary restrictions on evidence based prescribing pr...
Influence of medicare formulary restrictions on evidence based prescribing pr...Influence of medicare formulary restrictions on evidence based prescribing pr...
Influence of medicare formulary restrictions on evidence based prescribing pr...TÀI LIỆU NGÀNH MAY
 
MRSA poster ASB 2016SP
MRSA poster ASB 2016SPMRSA poster ASB 2016SP
MRSA poster ASB 2016SPCaroline Jones
 
Absolute risk estimation in a case cohort study of prostate cancer
Absolute risk estimation in a case cohort study of prostate cancerAbsolute risk estimation in a case cohort study of prostate cancer
Absolute risk estimation in a case cohort study of prostate cancersahirbhatnagar
 
Difference between cohort, cross sectional and case control study - Scientifi...
Difference between cohort, cross sectional and case control study - Scientifi...Difference between cohort, cross sectional and case control study - Scientifi...
Difference between cohort, cross sectional and case control study - Scientifi...Pubrica
 
SAMS EBM Online Course: Observational Study Designs
SAMS EBM Online Course: Observational Study DesignsSAMS EBM Online Course: Observational Study Designs
SAMS EBM Online Course: Observational Study DesignsAhmad Al-Moujahed
 
Steps in cohort study
Steps in cohort studySteps in cohort study
Steps in cohort studySachin Patne
 
Prevention mrsa.ppt.shirlhooper
Prevention mrsa.ppt.shirlhooperPrevention mrsa.ppt.shirlhooper
Prevention mrsa.ppt.shirlhooperShirl Hooper
 
A Review of Literature Addressing the Use of APRN Run Clinics to Decrease Cro...
A Review of Literature Addressing the Use of APRN Run Clinics to Decrease Cro...A Review of Literature Addressing the Use of APRN Run Clinics to Decrease Cro...
A Review of Literature Addressing the Use of APRN Run Clinics to Decrease Cro...Pam Davis,MSN, RN
 
Crp critical appraisal group 9 cohort
Crp   critical appraisal group 9 cohortCrp   critical appraisal group 9 cohort
Crp critical appraisal group 9 cohortMuhammadNuurFauzi
 
Methods Pyramids as an Organizing Structure for Evidence-Based Medicine--SIGC...
Methods Pyramids as an Organizing Structure for Evidence-Based Medicine--SIGC...Methods Pyramids as an Organizing Structure for Evidence-Based Medicine--SIGC...
Methods Pyramids as an Organizing Structure for Evidence-Based Medicine--SIGC...jodischneider
 
HSRPP 2015 IJPP pain
HSRPP 2015 IJPP painHSRPP 2015 IJPP pain
HSRPP 2015 IJPP painJoyce McSwan
 
Understanding the-value-of-case-reports-and-studies-in-the-context-of-clinica...
Understanding the-value-of-case-reports-and-studies-in-the-context-of-clinica...Understanding the-value-of-case-reports-and-studies-in-the-context-of-clinica...
Understanding the-value-of-case-reports-and-studies-in-the-context-of-clinica...Annex Publishers
 

Was ist angesagt? (20)

JournalofHospitalMedicine
JournalofHospitalMedicineJournalofHospitalMedicine
JournalofHospitalMedicine
 
Project 9 Poster SRF
Project 9 Poster SRFProject 9 Poster SRF
Project 9 Poster SRF
 
Fuller et al-2015-head_&amp;_neck
Fuller et al-2015-head_&amp;_neckFuller et al-2015-head_&amp;_neck
Fuller et al-2015-head_&amp;_neck
 
Cohort dr.wah
Cohort dr.wahCohort dr.wah
Cohort dr.wah
 
Influence of medicare formulary restrictions on evidence based prescribing pr...
Influence of medicare formulary restrictions on evidence based prescribing pr...Influence of medicare formulary restrictions on evidence based prescribing pr...
Influence of medicare formulary restrictions on evidence based prescribing pr...
 
MRSA poster ASB 2016SP
MRSA poster ASB 2016SPMRSA poster ASB 2016SP
MRSA poster ASB 2016SP
 
Cohort ppt
Cohort pptCohort ppt
Cohort ppt
 
Absolute risk estimation in a case cohort study of prostate cancer
Absolute risk estimation in a case cohort study of prostate cancerAbsolute risk estimation in a case cohort study of prostate cancer
Absolute risk estimation in a case cohort study of prostate cancer
 
Difference between cohort, cross sectional and case control study - Scientifi...
Difference between cohort, cross sectional and case control study - Scientifi...Difference between cohort, cross sectional and case control study - Scientifi...
Difference between cohort, cross sectional and case control study - Scientifi...
 
SAMS EBM Online Course: Observational Study Designs
SAMS EBM Online Course: Observational Study DesignsSAMS EBM Online Course: Observational Study Designs
SAMS EBM Online Course: Observational Study Designs
 
Using NHS Electronic Health Records for Research
Using NHS Electronic Health Records for ResearchUsing NHS Electronic Health Records for Research
Using NHS Electronic Health Records for Research
 
Cohort study
Cohort studyCohort study
Cohort study
 
Steps in cohort study
Steps in cohort studySteps in cohort study
Steps in cohort study
 
Prevention mrsa.ppt.shirlhooper
Prevention mrsa.ppt.shirlhooperPrevention mrsa.ppt.shirlhooper
Prevention mrsa.ppt.shirlhooper
 
A Review of Literature Addressing the Use of APRN Run Clinics to Decrease Cro...
A Review of Literature Addressing the Use of APRN Run Clinics to Decrease Cro...A Review of Literature Addressing the Use of APRN Run Clinics to Decrease Cro...
A Review of Literature Addressing the Use of APRN Run Clinics to Decrease Cro...
 
Crp critical appraisal group 9 cohort
Crp   critical appraisal group 9 cohortCrp   critical appraisal group 9 cohort
Crp critical appraisal group 9 cohort
 
Methods Pyramids as an Organizing Structure for Evidence-Based Medicine--SIGC...
Methods Pyramids as an Organizing Structure for Evidence-Based Medicine--SIGC...Methods Pyramids as an Organizing Structure for Evidence-Based Medicine--SIGC...
Methods Pyramids as an Organizing Structure for Evidence-Based Medicine--SIGC...
 
COHORT STUDY
COHORT STUDY COHORT STUDY
COHORT STUDY
 
HSRPP 2015 IJPP pain
HSRPP 2015 IJPP painHSRPP 2015 IJPP pain
HSRPP 2015 IJPP pain
 
Understanding the-value-of-case-reports-and-studies-in-the-context-of-clinica...
Understanding the-value-of-case-reports-and-studies-in-the-context-of-clinica...Understanding the-value-of-case-reports-and-studies-in-the-context-of-clinica...
Understanding the-value-of-case-reports-and-studies-in-the-context-of-clinica...
 

Andere mochten auch

Washington, Maastricht. Non stop to sudden stops
Washington, Maastricht. Non stop to sudden stopsWashington, Maastricht. Non stop to sudden stops
Washington, Maastricht. Non stop to sudden stopsFundación Ramón Areces
 
Telelingua Corporate Brochure 2016 - EN LRs
Telelingua Corporate Brochure 2016 - EN LRsTelelingua Corporate Brochure 2016 - EN LRs
Telelingua Corporate Brochure 2016 - EN LRsSven Lekeu
 
consumismo - la historia de las cosas
consumismo - la historia de las cosasconsumismo - la historia de las cosas
consumismo - la historia de las cosasluciamtz
 
Wichtich is' auf’er Webseite: Social Media Kanäle in der Web-Analyse abbilden
Wichtich is' auf’er Webseite: Social Media Kanäle in der Web-Analyse abbildenWichtich is' auf’er Webseite: Social Media Kanäle in der Web-Analyse abbilden
Wichtich is' auf’er Webseite: Social Media Kanäle in der Web-Analyse abbildencrowdmedia GmbH
 
Hack your Mindset- BRAIN UC Agosto 2015
Hack your Mindset- BRAIN UC Agosto 2015Hack your Mindset- BRAIN UC Agosto 2015
Hack your Mindset- BRAIN UC Agosto 2015Mindset Dynamics
 
Revista Mundo Contact Agosto 2015
Revista Mundo Contact Agosto 2015Revista Mundo Contact Agosto 2015
Revista Mundo Contact Agosto 2015Mundo Contact
 
Bedanl sinus a302_09.2009
Bedanl sinus a302_09.2009Bedanl sinus a302_09.2009
Bedanl sinus a302_09.2009thanurabw
 
The Next Web 2009 - Ruigrok | NetPanel
The Next Web 2009 - Ruigrok | NetPanelThe Next Web 2009 - Ruigrok | NetPanel
The Next Web 2009 - Ruigrok | NetPanelMarja Ruigrok
 
C18 manual
C18 manualC18 manual
C18 manualzan369
 
Ecología Gasoducto Vs. Energía electrica
Ecología Gasoducto Vs. Energía electricaEcología Gasoducto Vs. Energía electrica
Ecología Gasoducto Vs. Energía electricaChristopher Marrero
 
What is cultured pearl gemstones or moti ratna
What is cultured pearl gemstones or moti ratnaWhat is cultured pearl gemstones or moti ratna
What is cultured pearl gemstones or moti ratnaPearl Gemstone
 
Frederic Maire - Renault Innovation Silicon Valley - Stanford - Jan 30 2012 v2
Frederic Maire - Renault Innovation Silicon Valley - Stanford - Jan 30 2012 v2Frederic Maire - Renault Innovation Silicon Valley - Stanford - Jan 30 2012 v2
Frederic Maire - Renault Innovation Silicon Valley - Stanford - Jan 30 2012 v2Burton Lee
 

Andere mochten auch (18)

Enfermedad renal cronica ok
Enfermedad renal cronica okEnfermedad renal cronica ok
Enfermedad renal cronica ok
 
Washington, Maastricht. Non stop to sudden stops
Washington, Maastricht. Non stop to sudden stopsWashington, Maastricht. Non stop to sudden stops
Washington, Maastricht. Non stop to sudden stops
 
Telelingua Corporate Brochure 2016 - EN LRs
Telelingua Corporate Brochure 2016 - EN LRsTelelingua Corporate Brochure 2016 - EN LRs
Telelingua Corporate Brochure 2016 - EN LRs
 
TOPLOAD magazine
TOPLOAD magazineTOPLOAD magazine
TOPLOAD magazine
 
consumismo - la historia de las cosas
consumismo - la historia de las cosasconsumismo - la historia de las cosas
consumismo - la historia de las cosas
 
Wichtich is' auf’er Webseite: Social Media Kanäle in der Web-Analyse abbilden
Wichtich is' auf’er Webseite: Social Media Kanäle in der Web-Analyse abbildenWichtich is' auf’er Webseite: Social Media Kanäle in der Web-Analyse abbilden
Wichtich is' auf’er Webseite: Social Media Kanäle in der Web-Analyse abbilden
 
Chapter 2 computer software
Chapter 2 computer softwareChapter 2 computer software
Chapter 2 computer software
 
Qué Has Hecho Hoy?
Qué Has Hecho Hoy?Qué Has Hecho Hoy?
Qué Has Hecho Hoy?
 
Hack your Mindset- BRAIN UC Agosto 2015
Hack your Mindset- BRAIN UC Agosto 2015Hack your Mindset- BRAIN UC Agosto 2015
Hack your Mindset- BRAIN UC Agosto 2015
 
Revista Mundo Contact Agosto 2015
Revista Mundo Contact Agosto 2015Revista Mundo Contact Agosto 2015
Revista Mundo Contact Agosto 2015
 
OS Accelerate London - 09/16/15
OS Accelerate London - 09/16/15OS Accelerate London - 09/16/15
OS Accelerate London - 09/16/15
 
Bedanl sinus a302_09.2009
Bedanl sinus a302_09.2009Bedanl sinus a302_09.2009
Bedanl sinus a302_09.2009
 
The Next Web 2009 - Ruigrok | NetPanel
The Next Web 2009 - Ruigrok | NetPanelThe Next Web 2009 - Ruigrok | NetPanel
The Next Web 2009 - Ruigrok | NetPanel
 
02.09.13 blitzko
02.09.13 blitzko02.09.13 blitzko
02.09.13 blitzko
 
C18 manual
C18 manualC18 manual
C18 manual
 
Ecología Gasoducto Vs. Energía electrica
Ecología Gasoducto Vs. Energía electricaEcología Gasoducto Vs. Energía electrica
Ecología Gasoducto Vs. Energía electrica
 
What is cultured pearl gemstones or moti ratna
What is cultured pearl gemstones or moti ratnaWhat is cultured pearl gemstones or moti ratna
What is cultured pearl gemstones or moti ratna
 
Frederic Maire - Renault Innovation Silicon Valley - Stanford - Jan 30 2012 v2
Frederic Maire - Renault Innovation Silicon Valley - Stanford - Jan 30 2012 v2Frederic Maire - Renault Innovation Silicon Valley - Stanford - Jan 30 2012 v2
Frederic Maire - Renault Innovation Silicon Valley - Stanford - Jan 30 2012 v2
 

Ähnlich wie Doi 10.1016 j.msard.2016.09.007

The journal of law medicine ethics mapping
The journal of law medicine ethics mappingThe journal of law medicine ethics mapping
The journal of law medicine ethics mappingSC CTSI at USC and CHLA
 
Mito summit 2023 Sophia Zilber.pdf
Mito summit 2023 Sophia Zilber.pdfMito summit 2023 Sophia Zilber.pdf
Mito summit 2023 Sophia Zilber.pdfSophiaZilber
 
Participation of the population in decisions about their health and in the pr...
Participation of the population in decisions about their health and in the pr...Participation of the population in decisions about their health and in the pr...
Participation of the population in decisions about their health and in the pr...Pydesalud
 
AMIA 2015 CRI Year-in-Review
AMIA 2015 CRI Year-in-ReviewAMIA 2015 CRI Year-in-Review
AMIA 2015 CRI Year-in-ReviewPeter Embi
 
Colorectal Cancer Screening
Colorectal Cancer ScreeningColorectal Cancer Screening
Colorectal Cancer ScreeningRenzo Amaya
 
Global Medical Cures™ - Screening for Skin Cancer in Adults
Global Medical Cures™ - Screening for Skin Cancer in AdultsGlobal Medical Cures™ - Screening for Skin Cancer in Adults
Global Medical Cures™ - Screening for Skin Cancer in AdultsGlobal Medical Cures™
 
Explanation of how do individuals with multiple sclerosis cope with social is...
Explanation of how do individuals with multiple sclerosis cope with social is...Explanation of how do individuals with multiple sclerosis cope with social is...
Explanation of how do individuals with multiple sclerosis cope with social is...Liberty University (LU)
 
Running head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docx
Running head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docxRunning head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docx
Running head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docxtodd271
 
A Catalyst For Transforming Health Systems And Person-Centred Care Canadian ...
A Catalyst For Transforming Health Systems And Person-Centred Care  Canadian ...A Catalyst For Transforming Health Systems And Person-Centred Care  Canadian ...
A Catalyst For Transforming Health Systems And Person-Centred Care Canadian ...Becky Gilbert
 
human subject protection • summer 2019 213The Journal of Law
human subject protection • summer 2019 213The Journal of Lawhuman subject protection • summer 2019 213The Journal of Law
human subject protection • summer 2019 213The Journal of LawNarcisaBrandenburg70
 
journals to publish paper
journals to publish paperjournals to publish paper
journals to publish paperchaitanya451336
 
Of all the ways to influence health policy, using research to info.docx
Of all the ways to influence health policy, using research to info.docxOf all the ways to influence health policy, using research to info.docx
Of all the ways to influence health policy, using research to info.docxcherishwinsland
 
From personalized medicine to personalized science - a new concept in biogero...
From personalized medicine to personalized science - a new concept in biogero...From personalized medicine to personalized science - a new concept in biogero...
From personalized medicine to personalized science - a new concept in biogero...Anna Ericsson
 

Ähnlich wie Doi 10.1016 j.msard.2016.09.007 (20)

Translating research for health policy june 2014
Translating research for health policy   june 2014Translating research for health policy   june 2014
Translating research for health policy june 2014
 
The journal of law medicine ethics mapping
The journal of law medicine ethics mappingThe journal of law medicine ethics mapping
The journal of law medicine ethics mapping
 
Mito summit 2023 Sophia Zilber.pdf
Mito summit 2023 Sophia Zilber.pdfMito summit 2023 Sophia Zilber.pdf
Mito summit 2023 Sophia Zilber.pdf
 
Participation of the population in decisions about their health and in the pr...
Participation of the population in decisions about their health and in the pr...Participation of the population in decisions about their health and in the pr...
Participation of the population in decisions about their health and in the pr...
 
Observational Studies in a Learning Health System
Observational Studies in a Learning Health SystemObservational Studies in a Learning Health System
Observational Studies in a Learning Health System
 
AMIA 2015 CRI Year-in-Review
AMIA 2015 CRI Year-in-ReviewAMIA 2015 CRI Year-in-Review
AMIA 2015 CRI Year-in-Review
 
Colorectal Cancer Screening
Colorectal Cancer ScreeningColorectal Cancer Screening
Colorectal Cancer Screening
 
Engaging Patients in Research and Tool Development
Engaging Patients in Research and Tool DevelopmentEngaging Patients in Research and Tool Development
Engaging Patients in Research and Tool Development
 
Global Medical Cures™ - Screening for Skin Cancer in Adults
Global Medical Cures™ - Screening for Skin Cancer in AdultsGlobal Medical Cures™ - Screening for Skin Cancer in Adults
Global Medical Cures™ - Screening for Skin Cancer in Adults
 
Explanation of how do individuals with multiple sclerosis cope with social is...
Explanation of how do individuals with multiple sclerosis cope with social is...Explanation of how do individuals with multiple sclerosis cope with social is...
Explanation of how do individuals with multiple sclerosis cope with social is...
 
Running head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docx
Running head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docxRunning head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docx
Running head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docx
 
A Catalyst For Transforming Health Systems And Person-Centred Care Canadian ...
A Catalyst For Transforming Health Systems And Person-Centred Care  Canadian ...A Catalyst For Transforming Health Systems And Person-Centred Care  Canadian ...
A Catalyst For Transforming Health Systems And Person-Centred Care Canadian ...
 
human subject protection • summer 2019 213The Journal of Law
human subject protection • summer 2019 213The Journal of Lawhuman subject protection • summer 2019 213The Journal of Law
human subject protection • summer 2019 213The Journal of Law
 
scopus database journal
scopus database journalscopus database journal
scopus database journal
 
journals to publish paper
journals to publish paperjournals to publish paper
journals to publish paper
 
published research
published researchpublished research
published research
 
journal research paper
journal research paperjournal research paper
journal research paper
 
ugc carelist journals
ugc carelist journalsugc carelist journals
ugc carelist journals
 
Of all the ways to influence health policy, using research to info.docx
Of all the ways to influence health policy, using research to info.docxOf all the ways to influence health policy, using research to info.docx
Of all the ways to influence health policy, using research to info.docx
 
From personalized medicine to personalized science - a new concept in biogero...
From personalized medicine to personalized science - a new concept in biogero...From personalized medicine to personalized science - a new concept in biogero...
From personalized medicine to personalized science - a new concept in biogero...
 

Mehr von BartsMSBlog

Hellenic neuroimmunology
Hellenic neuroimmunologyHellenic neuroimmunology
Hellenic neuroimmunologyBartsMSBlog
 
Revised B cell covid vaccine review paper
Revised B cell covid vaccine review paperRevised B cell covid vaccine review paper
Revised B cell covid vaccine review paperBartsMSBlog
 
Academy baker debate blog
Academy baker debate blogAcademy baker debate blog
Academy baker debate blogBartsMSBlog
 
Baker At the Limits online
Baker At the Limits onlineBaker At the Limits online
Baker At the Limits onlineBartsMSBlog
 
Ali et al. 2020 biotechniques
Ali et al. 2020 biotechniquesAli et al. 2020 biotechniques
Ali et al. 2020 biotechniquesBartsMSBlog
 
Baker slides ectrims hot topic
Baker slides ectrims hot topic Baker slides ectrims hot topic
Baker slides ectrims hot topic BartsMSBlog
 
Baker ectrims teaching slides
Baker ectrims teaching slidesBaker ectrims teaching slides
Baker ectrims teaching slidesBartsMSBlog
 
Baker esni handouts slides
Baker esni handouts slidesBaker esni handouts slides
Baker esni handouts slidesBartsMSBlog
 
Baker esni handouts reading papers
Baker esni handouts reading papersBaker esni handouts reading papers
Baker esni handouts reading papersBartsMSBlog
 
Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)
Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)
Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)BartsMSBlog
 
Cladribine dhpc-01-12
Cladribine dhpc-01-12Cladribine dhpc-01-12
Cladribine dhpc-01-12BartsMSBlog
 
Cladribine dhpc-01-12
Cladribine dhpc-01-12Cladribine dhpc-01-12
Cladribine dhpc-01-12BartsMSBlog
 
Baker at the limitsfinalfor online
Baker at the limitsfinalfor onlineBaker at the limitsfinalfor online
Baker at the limitsfinalfor onlineBartsMSBlog
 
Baker lisbon peg
Baker  lisbon pegBaker  lisbon peg
Baker lisbon pegBartsMSBlog
 

Mehr von BartsMSBlog (20)

Hellenic neuroimmunology
Hellenic neuroimmunologyHellenic neuroimmunology
Hellenic neuroimmunology
 
Revised B cell covid vaccine review paper
Revised B cell covid vaccine review paperRevised B cell covid vaccine review paper
Revised B cell covid vaccine review paper
 
Academy baker debate blog
Academy baker debate blogAcademy baker debate blog
Academy baker debate blog
 
Baker At the Limits online
Baker At the Limits onlineBaker At the Limits online
Baker At the Limits online
 
Ms academy
Ms academyMs academy
Ms academy
 
Ali et al. 2020 biotechniques
Ali et al. 2020 biotechniquesAli et al. 2020 biotechniques
Ali et al. 2020 biotechniques
 
Baker slides ectrims hot topic
Baker slides ectrims hot topic Baker slides ectrims hot topic
Baker slides ectrims hot topic
 
Baker ectrims teaching slides
Baker ectrims teaching slidesBaker ectrims teaching slides
Baker ectrims teaching slides
 
Baker esni handouts slides
Baker esni handouts slidesBaker esni handouts slides
Baker esni handouts slides
 
Baker esni handouts reading papers
Baker esni handouts reading papersBaker esni handouts reading papers
Baker esni handouts reading papers
 
Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)
Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)
Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)
 
Cannabis
CannabisCannabis
Cannabis
 
Wc500240381
Wc500240381Wc500240381
Wc500240381
 
Cladribine dhpc-01-12
Cladribine dhpc-01-12Cladribine dhpc-01-12
Cladribine dhpc-01-12
 
Cladribine dhpc-01-12
Cladribine dhpc-01-12Cladribine dhpc-01-12
Cladribine dhpc-01-12
 
At the limits
At the limitsAt the limits
At the limits
 
Baker at the limitsfinalfor online
Baker at the limitsfinalfor onlineBaker at the limitsfinalfor online
Baker at the limitsfinalfor online
 
At the limits
At the limitsAt the limits
At the limits
 
Ectrims actrims
Ectrims actrimsEctrims actrims
Ectrims actrims
 
Baker lisbon peg
Baker  lisbon pegBaker  lisbon peg
Baker lisbon peg
 

Kürzlich hochgeladen

Call Girls Thane Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Thane Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Thane Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Thane Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Service In Goa 💋 9316020077💋 Goa Call Girls By Russian Call Girl...
Call Girls Service In Goa  💋 9316020077💋 Goa Call Girls  By Russian Call Girl...Call Girls Service In Goa  💋 9316020077💋 Goa Call Girls  By Russian Call Girl...
Call Girls Service In Goa 💋 9316020077💋 Goa Call Girls By Russian Call Girl...russian goa call girl and escorts service
 
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR Call G...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR   Call G...❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR   Call G...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR Call G...Gfnyt.com
 
Call Girls Chandigarh 👙 7001035870 👙 Genuine WhatsApp Number for Real Meet
Call Girls Chandigarh 👙 7001035870 👙 Genuine WhatsApp Number for Real MeetCall Girls Chandigarh 👙 7001035870 👙 Genuine WhatsApp Number for Real Meet
Call Girls Chandigarh 👙 7001035870 👙 Genuine WhatsApp Number for Real Meetpriyashah722354
 
Call Girls Service Faridabad 📲 9999965857 ヅ10k NiGhT Call Girls In Faridabad
Call Girls Service Faridabad 📲 9999965857 ヅ10k NiGhT Call Girls In FaridabadCall Girls Service Faridabad 📲 9999965857 ヅ10k NiGhT Call Girls In Faridabad
Call Girls Service Faridabad 📲 9999965857 ヅ10k NiGhT Call Girls In Faridabadgragmanisha42
 
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetBareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Service
 
❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF ...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF  ...❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF  ...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF ...Gfnyt.com
 
VIP Call Girls Noida Sia 9711199171 High Class Call Girl Near Me
VIP Call Girls Noida Sia 9711199171 High Class Call Girl Near MeVIP Call Girls Noida Sia 9711199171 High Class Call Girl Near Me
VIP Call Girls Noida Sia 9711199171 High Class Call Girl Near Memriyagarg453
 
Jaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
Jaipur Call Girls 9257276172 Call Girl in Jaipur RajasthanJaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
Jaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthanindiancallgirl4rent
 
Krishnagiri call girls Tamil aunty 7877702510
Krishnagiri call girls Tamil aunty 7877702510Krishnagiri call girls Tamil aunty 7877702510
Krishnagiri call girls Tamil aunty 7877702510Vipesco
 
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetbhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Service
 
Call Girl Raipur 📲 9999965857 ヅ10k NiGhT Call Girls In Raipur
Call Girl Raipur 📲 9999965857 ヅ10k NiGhT Call Girls In RaipurCall Girl Raipur 📲 9999965857 ヅ10k NiGhT Call Girls In Raipur
Call Girl Raipur 📲 9999965857 ヅ10k NiGhT Call Girls In Raipurgragmanisha42
 
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...indiancallgirl4rent
 
dhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
dhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetdhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
dhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Service
 
Chandigarh Call Girls 👙 7001035870 👙 Genuine WhatsApp Number for Real Meet
Chandigarh Call Girls 👙 7001035870 👙 Genuine WhatsApp Number for Real MeetChandigarh Call Girls 👙 7001035870 👙 Genuine WhatsApp Number for Real Meet
Chandigarh Call Girls 👙 7001035870 👙 Genuine WhatsApp Number for Real Meetpriyashah722354
 
VIP Call Girl Sector 10 Noida Call Me: 9711199171
VIP Call Girl Sector 10 Noida Call Me: 9711199171VIP Call Girl Sector 10 Noida Call Me: 9711199171
VIP Call Girl Sector 10 Noida Call Me: 9711199171Call Girls Service Gurgaon
 
(Ajay) Call Girls in Dehradun- 8854095900 Escorts Service 50% Off with Cash O...
(Ajay) Call Girls in Dehradun- 8854095900 Escorts Service 50% Off with Cash O...(Ajay) Call Girls in Dehradun- 8854095900 Escorts Service 50% Off with Cash O...
(Ajay) Call Girls in Dehradun- 8854095900 Escorts Service 50% Off with Cash O...indiancallgirl4rent
 
Jalna Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Jalna Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetJalna Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Jalna Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Service
 
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetnagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Service
 
Tirupati Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Tirupati Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetTirupati Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Tirupati Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Service
 

Kürzlich hochgeladen (20)

Call Girls Thane Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Thane Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Thane Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Thane Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Service In Goa 💋 9316020077💋 Goa Call Girls By Russian Call Girl...
Call Girls Service In Goa  💋 9316020077💋 Goa Call Girls  By Russian Call Girl...Call Girls Service In Goa  💋 9316020077💋 Goa Call Girls  By Russian Call Girl...
Call Girls Service In Goa 💋 9316020077💋 Goa Call Girls By Russian Call Girl...
 
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR Call G...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR   Call G...❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR   Call G...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR Call G...
 
Call Girls Chandigarh 👙 7001035870 👙 Genuine WhatsApp Number for Real Meet
Call Girls Chandigarh 👙 7001035870 👙 Genuine WhatsApp Number for Real MeetCall Girls Chandigarh 👙 7001035870 👙 Genuine WhatsApp Number for Real Meet
Call Girls Chandigarh 👙 7001035870 👙 Genuine WhatsApp Number for Real Meet
 
Call Girls Service Faridabad 📲 9999965857 ヅ10k NiGhT Call Girls In Faridabad
Call Girls Service Faridabad 📲 9999965857 ヅ10k NiGhT Call Girls In FaridabadCall Girls Service Faridabad 📲 9999965857 ヅ10k NiGhT Call Girls In Faridabad
Call Girls Service Faridabad 📲 9999965857 ヅ10k NiGhT Call Girls In Faridabad
 
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetBareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF ...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF  ...❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF  ...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Jaispreet Call Girl Services in Jaipur QRYPCF ...
 
VIP Call Girls Noida Sia 9711199171 High Class Call Girl Near Me
VIP Call Girls Noida Sia 9711199171 High Class Call Girl Near MeVIP Call Girls Noida Sia 9711199171 High Class Call Girl Near Me
VIP Call Girls Noida Sia 9711199171 High Class Call Girl Near Me
 
Jaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
Jaipur Call Girls 9257276172 Call Girl in Jaipur RajasthanJaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
Jaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
 
Krishnagiri call girls Tamil aunty 7877702510
Krishnagiri call girls Tamil aunty 7877702510Krishnagiri call girls Tamil aunty 7877702510
Krishnagiri call girls Tamil aunty 7877702510
 
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetbhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Call Girl Raipur 📲 9999965857 ヅ10k NiGhT Call Girls In Raipur
Call Girl Raipur 📲 9999965857 ヅ10k NiGhT Call Girls In RaipurCall Girl Raipur 📲 9999965857 ヅ10k NiGhT Call Girls In Raipur
Call Girl Raipur 📲 9999965857 ヅ10k NiGhT Call Girls In Raipur
 
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
 
dhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
dhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetdhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
dhanbad Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Chandigarh Call Girls 👙 7001035870 👙 Genuine WhatsApp Number for Real Meet
Chandigarh Call Girls 👙 7001035870 👙 Genuine WhatsApp Number for Real MeetChandigarh Call Girls 👙 7001035870 👙 Genuine WhatsApp Number for Real Meet
Chandigarh Call Girls 👙 7001035870 👙 Genuine WhatsApp Number for Real Meet
 
VIP Call Girl Sector 10 Noida Call Me: 9711199171
VIP Call Girl Sector 10 Noida Call Me: 9711199171VIP Call Girl Sector 10 Noida Call Me: 9711199171
VIP Call Girl Sector 10 Noida Call Me: 9711199171
 
(Ajay) Call Girls in Dehradun- 8854095900 Escorts Service 50% Off with Cash O...
(Ajay) Call Girls in Dehradun- 8854095900 Escorts Service 50% Off with Cash O...(Ajay) Call Girls in Dehradun- 8854095900 Escorts Service 50% Off with Cash O...
(Ajay) Call Girls in Dehradun- 8854095900 Escorts Service 50% Off with Cash O...
 
Jalna Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Jalna Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetJalna Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Jalna Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetnagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Tirupati Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Tirupati Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetTirupati Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Tirupati Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 

Doi 10.1016 j.msard.2016.09.007

  • 1. 1 ©2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ Multiple Sclerosis and Related Disorders. DOI: 10.1016/j.msard.2016.09.007 How to refer to people with disease in research outputs: The disconnection between academic practice and that preferred by people with multiple sclerosis. David Bakera ; Ananthi Anandhakrishnana ; Katie A. Tuite-Daltonb ; Hazel Lockart –Jonesb ; Rodden M. Middletonb ; David V. Fordb ; Christina Crowec ; Gavin Giovannonia 1 Neuroimmunology Unit, Blizard Institute, Barts and the London, Queen Mary University of London 2 College of Medicine, Swansea University, Swansea, Wales, United Kingdom 3 North American Research Committee on Multiple Sclerosis (NARCOMS), The University of Alabama at Birmingham, Birmingham, Alabama, USA Correspondence: Prof. D. Baker, Neuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom Tel: +44 20 7882 8954; Fax: +44 20 7882 2180; Email: david.baker@qmul.ac.uk HIGHLIGHTS  Someone who has MS prefers to be described as a “person with MS”  People with MS do not want to be referred to as a “sufferer” or “client”  Researchers largely used the term “Patient”, which is not particularly liked by people with MS  A simple change to practises of use of descriptors of MS may help the Patient and Public Involvement (PPI) process
  • 2. 2 ABSTRACT BACKGROUND: Increasingly, Government and Charity funders require public engagement in research. Invariably these research outputs describe the condition of someone with the disease of interest. We therefore sought to identify the preferred descriptor of someone with a disease, such as multiple sclerosis (MS) and to determine what descriptors are currently used by academics. METHODS: Several surveys were undertaken: one from the Research Network of the MS Society (MSSRN), a major MS Charity within the United Kingdom, who are involved in reviewing grant applications, priority setting and research governance (n=146), and surveys from both the United Kingdom MS register (MSR; n=1713) and the North American Research Committee on Multiple Sclerosis (NARCOMS) registry (n=518). People were asked to rate descriptors of someone affected with MS. These were compared to that used by academic experimenters in basic science and clinical science research papers. RESULTS: Although the frequency of responses varied between surveys the overall findings showed many consistencies. This included use of person/people with MS (pwMS) as the preferred descriptor for someone with MS for social media and scientific publications. This was the preferred choice in about 55-60% people from the MRS and in over 70% in the NARCOMS and the MSSRN, respectively. Although MSer was the second preferred–choice for use in social media, there was as a large range of preferences from the ‘most-preferred’ to the ‘most-disliked.’ This reflected an earlier survey by UK-based research blogs using the term MSer (n=173). In contrast, pwMS had few ‘dislikes’ and results were skewed towards the ‘liked’ and ‘most-preferred’ choices. Client and sufferer were generally disliked terms, although there was some regional variation in levels of choice. Patient was generally seen as a neutral term that was neither strongly liked nor disliked. However, patient gained more public support for use within scientific publications (~20-25%) compared to social media (~10–15%). This descriptor was however most commonly used (98–99%) within both pre- clinical (searched in 6-month output of preclinical autoimmune MS models; n=161) and in clinical publications (specialist MS journals; n=220), whereas pwMS was not reported in over 75% of papers published in some specialised MS journals, and did not appear in the pre-clinical animal studies examined. CONCLUSION: There is a clear disconnection between preferences by individuals living with MS and current academic practise. As pwMS are increasingly reading primary research publications and are involved in patient and public involvement in research and grant review activities, the sensitivities of lay readers should be considered when writing research outputs. This issue may affect other diseases and a change in writing style could be adopted to show that we respect the wishes of the people that we study and wish to help. KEYWORDS multiple sclerosis; public engagement; patient public Involvement; social media; surveys ABBREVIATIONS IQ Intelligence Quotient MS Multiple Sclerosis MSR MS Register MSSRN MS Society Research Network NARCOMS North American Research Committee on Multiple Sclerosis PPI patient and public involvement PwMS person/people with MS
  • 3. 3 1. INTRODUCTION Multiple sclerosis (MS) is an immune-mediated, demyelinating and neurodegenerative disease of the central nervous system that affects about 2.5 million people worldwide (Compston & Coles 2008). The disease is insufficiently controlled by currently available treatments and therefore people utilize the internet to investigate research and treatments options (Brigo et al. 2014). There is a an increasing will amongst Government and Charity funders of research that there is patient and public involvement (PPI) in research and a strong aspect of public engagement in science. This includes the production of ‘open access’ research outputs, such that people paying for the research have access to the findings. This supports the development of an increasingly knowledgeable number of people with MS, who are reading original academic articles as they try to understand their disease and treatment options. Furthermore, members of the public are involved in review panels for ethics and research grant applications, all of which require a lay summary as part of the funding process. To find a neutral term that best describes someone with MS, is empowering for people living with the disease, is non-patronizing and does not entrench stereotypes, we performed some surveys centred on web-based questionnaires (n=396) in which MSer was identified (Baker et al. 2014a). In our initial studies, people with MS (pwMS) did not like being called client, which is a ‘politically- correct’ term used by health economists, but also preferred not to be called a patient or an MS sufferer. In contrast pwMS received a good deal of support. The original surveys were from people visiting a United Kingdom (UK)–based, MS research blog (www.ms-res.org) and ShiftMS (www.shift.ms), which is a social media community for young people affected by MS. These sites used the term ‘MSer’, originating from the founders of ShiftMS, and therefore may have influenced the preferences of people taking the surveys. Therefore to examine this is further, different groups of people with MS were surveyed and the results were compared to that used by the academic community. 2. METHODS 2.1 Multiple Sclerosis Society Research Network Survey In consulting with the Queen Mary University of London Research Ethics Committee no personal identifiers were collected as part of this and previous surveys (Baker et al. 2014a). By completing the surveys, participants provided implied consent for publication of results, as indicated by disclaimers. A web link to an anonymous survey was sent, via the Multiple Sclerosis Society in the United Kingdom, to members (n=315) of the MS Society Research Network (MSSRN). This is a PPI network of people personally affected by MS, who are involved in priority setting, reviewing grant applications, governance of the research programme, advisory groups and other ad hoc PPI activities. (www.mssociety.org.uk/ms-research/get-involved-in-research/research-network). People in the MSSRN survey were asked how someone with MS should be referred to with 5 set options (Client; MSer; Sufferer; Patient; PwMS that were selected previously (Baker et al. 2014a)), and asked to rank these on a 1–5 scale, from most preferred to least preferred. 2.2 UK MS Register The UK MS Register (MSR) received peer review via MS Society mechanisms and has ethical approval from the South West–Central Bristol Research Ethics Committee (11/SW/0160) as a research database (Ford et al. 2012). Although identifiable information was collected via the MS register, this was only used to create data linkages such that the functioning UK MS Register contains only anonymous data accessed and analysed within a Safe Haven environment, with scrutiny of research outputs before release (Ford et al. 2012; Jones et al. 2014). The survey was performed, hosted and analysed by the UK MS register. 2.3 North American Research Committee on Multiple Sclerosis registry North American Research Committee on Multiple Sclerosis (NARCOMS) registry (www.narcoms.org; Kister et al. 2013) following ethical review by the University of Alabama at Birmingham (UAB) Institutional Review Board, sent the link to the original survey circulated to the MSSRN, to the NARCOMS registry.
  • 4. 4 2.4 Academic use of descriptors of pwmS. As part of a previous study [Baker et al. 2014b], 161 primary research papers concerned with experimental autoimmune encephalomyelitis studies, which were published over a six-month period in 2012 had been downloaded [Baker et al. 2014b]. These were analysed for which descriptors were used. In addition the total publication outputs of some MS specialist clinical journals for the same year were analysed. We searched papers in: Multiple Sclerosis and Related Disorders (n=42), Multiple Sclerosis Journal (n=220) and Multiple Sclerosis International (n=23). These were read to determine which descriptors were used. 3. RESULTS 3.1 The preferential descriptor for someone with multiple sclerosis-The patient perspective Following surveying the research network of the Multiple Sclerosis Society there were n=146 responses. The vast majority of people (about 70% of preferred responses in MSSRN) preferred the use of pwMS, while client was the least preferred (about 2–3% of the preferred responses) (Table 1; Figure 1). Although MSer was the second choice by the MSSRN for use in social media (Table 1), it was clear this was either a most-liked or disliked term, as also found in a sub-study (n=173) of the original surveys (Baker et al. 2014a) undertaken (Figure 1). In the survey of the MSSRN about 49% of responses selected MSer as a first or second (Preferred) choice, compared to 95% pf responses for pwMS, which was universally preferred, and 11% of the responses for client, which was the least preferred (Figure 1). Similarly 34% of responses that selected MSer were the last and second from last choices (Disliked) compared to 1% for pwMS or 70% for client (Figure 1). Patient was neither really liked (25% of response for patient) or disliked (36% of responses for patient) and most responses (39%) centred on the median preference. However, for use in scientific papers about 48% of the two most-preferred choices liked the use of patient compared to about 18% who disliked the use of patient. Again 96% of the top two responses preferred the use of pwMS and 0% of the two least-preferred responses disliked the use of pwMS. Thus, there were similarities in the overall types of responses in this new survey compared to one of the original surveys (Baker et al. 2014a), which addressed the same questions (Figure 1), although it was clear that pwMS was the preferred choice. To achieve independent replication, the survey was performed, hosted and analysed by the UK MS register. There were a total of 1713 responses to the survey over a two-week period and as per protocol, only completed responses were included in the analysis. Again there was a clear preference (54–58%) for the use of pwMS as a descriptor of someone with MS. Incomplete answers in the other surveys tended to only include 1–3 choices, often with pwMS as the most preferred, and this figure may therefore slightly underestimate the clear preference for use of pwMS. Likewise, again use of client was an infrequently preferred choice (6% of responses) (Table 1. Figure 2). MSer again had some preference for use in the social media (Table 1), but was again found to be a term that was either liked or disliked (Figure 2). Similarly, the use of MS sufferer was either disliked or liked with a trend for the term to be disliked in both social media and the academic literature (Figure 2). Whilst MSer may lack familiarity and thus account for the wide range of preferences observed (Figure 1, Figure 2), opinion may change as indicated by a more positive view from pwMS about MSer surveyed from sites that use the descriptor (Figure 1). Again, most notably in relation to use for social media, the use of patient was neither liked nor disliked (Figure 2). However, there was a greater preference for the use of patient in scientific publications (Table1; Figure 2). Thus, the trends identified in this large survey reflect those found in the smaller UK–based surveys (Figure 1; Figure 2). The web link used by the MSSRN was also hosted by the NARCOMS registry. Again, the preferred descriptor was pwMS for use in both social and academic media (n=518; Table 2; Figure 3). Similar to surveys by the MSSRN and MSR, here the preference for use of MSer was wide ranging. Likewise, patient was also neither most liked nor disliked for use in social media, although again use of patient was considered more acceptable in scientific outputs (Table 1; Figure 3). Client again tended to be disliked, although there appeared to be a greater acceptance of this politically-correct term than in the UK-based surveys (Figure 1-3). Likewise, use of the term sufferer suggested some national differences in acceptance of descriptor terms (Figure 3). Sufferer was largely disliked in the North American NARCOMS survey compared to the British MSR survey (Figure 3). As such, 33.6% of MSR
  • 5. 5 respondents “liked” or “most preferred” the use of sufferer, compared to only 14% of people in North America (P<0.001 Chi-squared Test). The underlying reasons behind this difference require further investigation, however the United Kingdom has poor access to disease modifying treatments (Kobelt & Kasteng 2009) and thus may be more likely to feel that they are suffering. Nevertheless in conclusion, it is clear that pwMS is the universally preferred descriptor of someone with MS for both social media and academic research outputs. 3.2 The preferential descriptor for someone with multiple sclerosis-Academic use In an attempt to determine what descriptors MS researchers use (Table 2), we analysed primary research papers concerned with experimental autoimmune encephalomyelitis (EAE) studies (n=161), published over 6 months [Baker et al. 2014b]. We also analysed the total publication outputs of some MS specialist clinical journals for the same year. In these journals we found that 114 pre- clinical, basic science papers about EAE described someone with MS. In the vast majority (98%) of cases, patient was used to describe someone with MS. Additional descriptors were used and MS sufferer or someone suffering from MS was used in 8% of papers describing pre-clinical studies (Table 2). However, this term did not appear in the papers in clinical journals examined (Table 1). Basic scientists sometimes also use MS sufferer, in their grant applications (unpublished observations). However, it is clear that academics largely use patient, as this occurred in 98-99% of published papers (although about a quarter of papers published in clinically-oriented journals used pwMS (Table 2)). Therefore there is a disconnection between that used by MS researchers and that preferred by pwMS. 4. DISCUSSION There is clearly a disconnection between pwMS-preference and that used by academia, suggesting that change is needed. As lay pwMS are commonly reading and appraising research grants as part of the PPI process, academics should consider the sensitivities of how best to refer to someone with MS. Simple consideration to these issues should be made during grant and paper-writing, as they are simple to implement. Although sufferer, which is more common in the tabloid media, was not commonly used in the medical journals, patient has its origins in Latin from the verb pati, to suffer, and through the participle form patientem, for one who is suffering. Patient is currently defined as a person who is under medical care or treatment and thus still carries a perhaps an out-dated paternalistic aura. This may need change as modern medicine evolves and decision-making is becoming a shared experience between the patient and caregiver. The medical profession has a history of being adaptive to change in relation to the description of people in their care; for example, the historical, medical use of: moron (Intelligence Quotient (IQ) <25), imbecile (IQ25-50) and idiot (IQ 50-70) as a measure of mild, moderate and profound mental retardation has ceased, as their use is considered politically incorrect and offensive by society. Concern has been expressed that any form of label can be used as a means for division and prejudice. With the need to have descriptors, the term pwMS was the preferred method for current description. This should be used in preference to ‘patient’ and use of both MS sufferer and MS client should be avoided. Whilst this aspect has been examined here in relation to MS, it is probably unlikely that the academic use of ‘patient’ and preference for ‘person with’ to describe any other condition is not the current norm. Therefore, a simple change in writing style could and should be adopted, if we are to show that we respect the wishes of the people that we serve and wish to help. FUNDING: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. ACKNOWLEDGEMENTS: The authors thank the assistance of the Multiple Sclerosis Society, notably Ms. Mital Patel. The MS Register gratefully acknowledges the support of the Multiple Sclerosis Society. NARCOMS acknowledges support from the Consortium of Multiple Sclerosis Centers, the National Multiple Sclerosis Society and unrestricted grants from pharmaceutical companies. CONFLICTS OF INTEREST: None relevant
  • 6. 6 REFERENCES Baker D, Pepper G, Yauner F, Giovannoni G. MSer - A new, neutral descriptor for someone with multiple sclerosis. Mult Scler Relat Disord. 2014a; 3:31-33. Baker D, Lidster K, Sottomayor A, Amor S. Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies. PLoS Biol. 2014b; 12:e1001756. Brigo F, Lochner P, Tezzon F, Nardone R. Web search behavior for multiple sclerosis: An infodemiological study. Mult Scler Relat Disord. 2014; 3:440-443. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372:1502-1517. Ford DV, Jones KH, Middleton RM, Lockhart-Jones H, Maramba ID, Noble GJ, Osborne LA, Lyons RA. The feasibility of collecting information from people with Multiple Sclerosis for the UK MS Register via a web portal: characterising a cohort of people with MS. BMC Med Inform Decis Mak. 2012; 12:73. Jones KH, Jones PA, Middleton RM, Ford DV, Tuite-Dalton K, Lockhart-Jones H, Peng J, Lyons RA, John A, Noble JG. Physical disability, anxiety and depression in people with MS: an internet-based survey via the UKMS Register. PLoS One. 2014; 9:e104604. Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Herbert J. Natural history of multiple sclerosis symptoms. Int J MS Care. 2013; 15: 146-158. Koberlt G, Kasteng F. Access to innovative treatments in multiple sclerosis in Europe. 2009, pg3:1- 3:20 European Federations of Pharmaceutical Industry Associations.
  • 7. 7 Table1 Descriptors most preferred by People with MS to describe someone with MS Most preferred descriptor of someone with multiple sclerosis Descriptor MS Blog MSS Research Network NARCOMS UK MS Register Social Academic Social Academic Social Academic Client 2% 3% 2% 4% 3% 6% 6% MSer 47% 18% 5% 11% 3% 17% 12% pwMS 42% 70% 67% 76% 67% 58% 54% Patient 10% 3% 15% 7% 23% 9% 21% Sufferer 6% 8% 14% 2% 4% 12% 16% Anonymous surveys were undertaken via: a MS blog site (n=174. Baker et al. 2014a); the UK MS Society Research Network (n=146); NARCOMS (n=518) and the UK MS Register (n=1731). It was requested that respondents ranked their most preferred descriptor for being referred to in either the social media or within academic media. In the MS Blog, MSSRN and NARCOMS surveys some responses recorded equal preferences. In the MS register survey, only data from fully competed surveys with a single preference were included in the analysis (n=1582–1618). Table2 Descriptors used to describe someone with MS in academic papers Frequency of descriptor of someone with multiple sclerosis in academic papers Descriptor Basic Science Papers Clinical MS Special Journals Client 0% 0% MSer 0% 0% pwMS 1% 24% Patient 98% 99% Sufferer 8% 0% Published papers on pre-clinical studies using animal models of MS (n=114) and papers published in clinically-related, MS-specialist journals (n=285) were read and frequency of the descriptor, which may have contained multiple descriptors within one study, used to describe of someone with MS was recorded.
  • 8. 8 Figure 1. Preferred descriptors used to describe someone with MS FrequencyofResponses(%) 0 10 20 30 40 50 60 0 10 20 30 40 50 60 FrequencyofResponses(%) CLIENT MSer 0 10 20 30 40 50 60 MSer 0 10 20 30 40 50 60 PATIENT 0 10 20 30 40 50 60 PATIENT FrequencyofResponses(%) FrequencyofResponses(%)FrequencyofResponses(%) 0 10 20 30 40 50 60 CLIENT Most Disliked FrequencyofResponses(%) 0 10 20 30 40 50 60 Neutral Response Most Liked Disliked Liked CLIENT 0 10 20 30 40 50 60 70 80 PERSON WITH MS 0 10 20 30 40 50 60 MS RESEARCH BLOG PREFERENCE CHARITY RESEARCH NETWORK PREFERENCE FrequencyofResponses(%) Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked FrequencyofResponses(%) MS SUFFERER 0 10 20 30 40 50 60 Most Disliked Neutral Response Most Liked Disliked Liked MS SUFFERER Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked PERSON WITH MS FrequencyofResponses(%) Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked An anonymous survey was undertaken via (a) an MS research blog (Baker et al. 2014a) and (b) the MS Society Research Network. It was requested that respondents ranked the quality of/their most preferred descriptor for being referred to. The data represent the frequency distribution or each preference on the research blog (n=173) or preference of how to describe someone with MS on Social media (n=111–140).
  • 9. 9 Figure 2. Preferred descriptors used to describe someone with MS on the UK MS Register FrequencyofResponses(%) 0 10 20 30 40 50 60 0 10 20 30 40 50 60 FrequencyofResponses(%) CLIENT MSer 0 10 20 30 40 50 60 MSer 0 10 20 30 40 50 60 PATIENT 0 10 20 30 40 50 60 PATIENT FrequencyofResponses(%) FrequencyofResponses(%)FrequencyofResponses(%) 0 10 20 30 40 50 60 CLIENT Most Disliked FrequencyofResponses(%) 0 10 20 30 40 50 60 Neutral Response Most Liked Disliked Liked CLIENT 0 10 20 30 40 50 60 PERSON WITH MS 0 10 20 30 40 50 60 SOCIAL MEDIA PREFERENCE SCIENTIFIC PUBLICATION PREFERENCE FrequencyofResponses(%) Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked FrequencyofResponses(%) MS SUFFERER 0 10 20 30 40 50 60 Most Disliked Neutral Response Most Liked Disliked Liked MS SUFFERER Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked PERSON WITH MS FrequencyofResponses(%) Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked A survey was undertaken via the UK MS Register. It was requested that respondents ranked their most preferred descriptor for being referred to in either: Social Media or within Academic Publications. The data represent the frequency distribution or each preference from fully completed surveys that used recorded only a single preference (n=1582–1618).
  • 10. 10 Figure 3. Preferred descriptors used to describe someone with MS on the NARCOMS registry FrequencyofResponses(%) 0 10 20 30 40 50 60 0 10 20 30 40 50 60 FrequencyofResponses(%) CLIENT MSer 0 10 20 30 40 50 60 MSer 0 10 20 30 40 50 60 PATIENT 0 10 20 30 40 50 60 PATIENT FrequencyofResponses(%) FrequencyofResponses(%)FrequencyofResponses(%) 0 10 20 30 40 50 60 70 80 Most Disliked FrequencyofResponses(%) 0 10 20 30 40 50 60 Neutral Response Most Liked Disliked Liked CLIENT 0 10 20 30 40 50 60 70 80 PERSON WITH MS 0 10 20 30 40 50 60 SOCIAL MEDIA PREFERENCE SCIENTIFIC PUBLICATION PREFERENCE FrequencyofResponses(%) Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked FrequencyofResponses(%) MS SUFFERER 0 10 20 30 40 50 60 Most Disliked Neutral Response Most Liked Disliked Liked MS SUFFERER Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked PERSON WITH MS FrequencyofResponses(%) Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked Most Disliked Neutral Response Most Liked Disliked Liked An anonymous survey was undertaken via the NARCOMS registry website (www.narcoms.org). It was requested that respondents ranked their most preferred descriptor for being referred to in either: Social Media or within Academic Publications. The data represent the frequency distribution of each preference (n=454–509).